Alectinib, brigatinib, and lorlatinib have all been demonstrated in clinical trials (Alex, ALTA-1L, and Crown) to have superior efficacy to crizotinib in the primary treatment of ALK-positive NSCLC (36–38). The gene discussed is ALK; the disease is non-small cell lung carcinoma.